Crown Bioscience Zhongshan recently opened in Tsuihang New District (THND). It is the Zhongshan branch of CrownBio, a global prescription drug discovery and development company. It is also CrownBio's fifth branch company in China after Beijing, Taicang, Suzhou and Taiwan.

CrownBio was founded in Silicon Valley, California in 2006, and it has now developed into a globally-renowned tumor and diabetes drug efficacy testing technology company.

Crown Bioscience Zhongshan has completed the first phase of its project. It has a BSL-2 laboratory for scientific research and R&D projects, and is equipped with a state of the art ABSL-2 animal testing room. Crown Bioscience Zhongshan is expected to be fully operational by 2021.

Kevin Wang Liandu, vice president and managing director China of CrownBio, said Crown Bioscience Zhongshan would develop into CrownBio's largest base in China in the future.